Cohance Lifesciences logo

Cohance Lifesciences financials and balance sheet

NSE: COHANCEBSE: 543064Pharmaceuticals & BiotechnologySmall Cap

Formerly Suven Pharmaceuticals
Last close ₹449.85down ₹4.00 (0.88%)BSE ₹448.65

Share price at the NSE close on 23 Oct 2026. Previous close ₹453.85.

52-week range of traded prices to 23 Oct 2026
₹266.70Low, 9 Mar 2026₹903.40High, 23 Oct 2025
Market cap
₹17,211 Cr428th largest listed
P/E
162.0
P/E without one-offs
134.9
P/B
4.4
Dividend yield
Nonein the last 12 months
ROE
3.8%
ROE without one-offs
4.6%
ROCE
3.0%
Debt to equity
0.04
Volume, NSE
5,73,70251.1% delivered

7 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Cohance Lifesciences annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹2,269 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue2,269
  2. Materials and goods−663
  3. Employee costs−508
  4. Other expenses−671
  5. Operating profit427
  6. Depreciation−187
  7. Other income+34
  8. One-off items−29
  9. Finance costs−37
  10. Profit before tax207
  11. Tax−57
  12. Net profit150

What the company owns

  • Plant, investments and other assets₹4,160 Cr
  • Receivables₹681 Cr
  • Inventory₹562 Cr
  • Current investments₹266 Cr
  • Cash and bank₹60 Cr

What pays for it: net worth and liabilities

  • Net worth₹4,034 Cr
  • Other liabilities₹1,242 Cr
  • Owed to suppliers₹285 Cr
  • Borrowings₹170 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Cohance Lifesciences quarterly results

₹ croreMar 2020Filed 19 JunMar 2021Filed 9 JunMar 2022Filed 10 MayMar 2023Filed 26 MayMar 2024Filed 1 JunMar 2025Filed 13 JunMar 2026Filed 12 May
Revenue from operations8341,0101,3201,3401,0511,1982,269
4495697417746468221,842
Materials and goods bought229302399409315305663
Employee costs7476100111136250508
Other expenses146191241254195268671
Operating profit before depreciation385440579567406375427
Operating margin46.2%43.6%43.9%42.3%38.6%31.3%18.8%
Materials, % of revenue27.5%29.9%30.2%30.5%30.0%25.5%29.2%
Employee costs, % of revenue8.8%7.5%7.6%8.2%12.9%20.8%22.4%
Other expenses, % of revenue17.5%18.9%18.3%19.0%18.5%22.3%29.6%
Depreciation and amortisation243239485577187
Operating profit after depreciation361409540519351298240
Other income18149246625934
Finance costs2396571237
Profit before one-off items and tax356414626560406344237
One-off items000000−29
Profit before tax356414626560406344207
881052141481057957
Share of profit of joint ventures and associates485441––––
317362454411300265150
Other comprehensive income−1−1−10131399
Total comprehensive income316362453411313278249
Net margin38.0%35.9%34.4%30.7%28.6%22.1%6.6%
Net margin without joint ventures and associates32.2%30.6%31.3%––––

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2020Filed 19 JunMar 2021Filed 9 JunMar 2022Filed 10 MayMar 2023Filed 26 MayMar 2024Filed 1 JunMar 2025Filed 13 JunMar 2026Filed 12 May
8451,1811,5271,7352,0511,8414,034
8451,1811,5271,7352,0511,6973,911
Share capital13252525252538
Reserves8321,1551,5021,7102,0251,6713,873
Belonging to outside owners of subsidiaries0––––144123
18614196693978170
200220210159107365646
128749272978261,050
1,1731,4741,8301,9662,2543,0325,730
7819107029559912,1433,902
3925651,1281,0111,2638531,796
Net debt141−49−433−418−786−202−156
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Filed 9 JunMar 2022Filed 10 MayMar 2023Filed 26 MayMar 2024Filed 1 JunMar 2025Filed 13 JunMar 2026Filed 12 May
383330451358288368
493514617468372436
−11−194647−3221
Receivables13−136124−23−148103
Inventories−26−82−298274−95
Payables1223−41−284213
Other working capital−101−491700
Tax paid−109−184−146−110−83−68
Capital spending1117528652156220
Free cash flow273255165307132148
−311−136−195−362−255−255
−77−156−236−143−165
Dividends paid25102204000
Shares bought back000000
Shares issued0000032
Net change in cash−53720−1836−51
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the year to Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Cohance Lifesciences dividend history

₹ per shareMar 2020Filed 19 JunMar 2021Filed 9 JunMar 2022Filed 10 MayMar 2023Filed 26 MayMar 2024Filed 1 JunMar 2025Filed 13 JunMar 2026Filed 12 May
₹12.46₹14.23₹17.83₹16.16₹11.80₹10.52₹4.69
As stated that year₹24.91₹14.23₹17.83₹16.16₹11.80₹10.52₹4.69
₹12.46₹14.23₹17.83₹16.16₹11.80₹10.45₹4.68
Dividend per share–₹2.00₹5.00₹6.00–––
₹33.18₹46.39₹59.99₹68.16₹80.56₹66.64₹102.23
Dividend payout–14.1%28.0%37.1%–––
Shareholder yield–0.2%0.6%1.7%0.0%0.0%−0.3%
Market cap at the year end (₹ crore)2,55912,64715,74412,02617,23729,30011,532
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Consolidated, years to March.Cohance Lifesciences PE ratio and valuation

RatioMar 2020Filed 19 JunMar 2021Filed 9 JunMar 2022Filed 10 MayMar 2023Filed 26 MayMar 2024Filed 1 JunMar 2025Filed 13 JunMar 2026Filed 12 May
Revenue growth–21.1%30.8%1.5%−21.6%13.9%89.4%
Operating profit growth–14.4%31.5%−2.2%−28.4%−7.5%13.8%
Net profit growth–14.3%25.2%−9.4%−27.0%−11.8%−43.3%
Earnings per share growth–14.3%25.3%−9.4%−27.0%−10.8%−55.4%
37.5%35.8%33.5%25.2%15.9%14.3%6.4%
–−1.7 pts−2.3 pts−8.3 pts−9.4 pts−1.6 pts−7.9 pts
From the net margin–−2.1 pts−1.5 pts−3.6 pts−1.7 pts−3.4 pts−9.2 pts
From asset turnover–2.6 pts1.6 pts−3.5 pts−6.9 pts−1.1 pts0.7 pts
From borrowing–−2.2 pts−2.4 pts−1.2 pts−0.7 pts3.0 pts0.6 pts
Return on capital employed35.0%30.9%33.3%28.8%16.8%15.5%5.7%
Cash conversion–105.8%72.7%109.6%119.4%108.8%245.4%
Interest cover15.744.786.795.447.124.16.4
Debt to equity0.220.120.060.040.020.040.04
Receivable days513765304687110
Inventory days278243259279268199310
Payable days11310097584996157
Cash conversion cycle, days217180228251265190263
Working capital days1059412611712985152
Asset turnover0.710.760.800.710.500.450.52
Assets per rupee of net worth1.391.311.221.161.111.411.56
Sales per rupee of plant2.362.312.492.291.851.201.14
Capital spending to depreciation–3.501.925.990.952.011.17
Plant being built, % of plant in use28.8%22.0%5.7%28.3%31.6%25.6%8.7%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
4.1%
Cash from operations against operating profit
86.3%
Measure5 years3 years
Revenue growth, yearly rate17.6%19.2%
Profit growth, yearly rate−13.1%−24.2%
Return on equity, average19.1%12.2%
Return on capital employed, average20.0%12.7%
Operating margin, average35.0%29.6%
Net margin, average24.5%19.1%
Asset turnover, average0.600.49
Cash conversion cycle, days, average239239
Interest cover, average52.025.9
Debt to equity, average0.040.03

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations1,7961,015368
Cash from investing−1,203−872−255
Cash from financing−568−176−165
Capital spending788427220
Dividends paid30500
Shares bought back000
Shares issued for cash323232
Borrowings raised–250
Borrowings repaid16312794

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––66745
Altman Z-scorePublished threshold 1.817.6528.8534.8534.6653.7816.515.80
Beneish M-scorePublished threshold −1.78–−2.80−1.43−1.61−2.20−1.42−1.69
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–21.9315.738.1814.418.770.83
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––0.950.981.121.42
Receivables growth less revenue growthOur threshold 0 percentage points–−33.74100.12−54.5942.0498.9049.99
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–−16.768.777.86−3.09−24.86120.48
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–1.610.651.55−2.574.044.30
Assets under construction, years of additionsOur threshold 2 years of additions–0.830.231.634.760.500.15
Effective tax ratePublished threshold 17.16 per cent24.5625.4534.1226.5225.9823.0127.49
Tax charged less tax paid, % of profitOur threshold 10 percentage points––4.710.47−1.12−1.25−5.24
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
12 Aug 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesCrisil BB/Issuer Not Cooperating (Withdrawn)Review, OtherStable67
12 Aug 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesCrisil A4+/Issuer Not Cooperating (Withdrawn)Review, Other5.50
3 Dec 2025India Ratings and Research Private Limited (opens in a new tab)Bank loan facilitiesIND AA; IND A1+New, NewStable685
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.